Silent Killer: Scientists Fight a New Threat to Humanity
- researchers at the Massachusetts Institute of Technology are developing a novel vaccine candidate targeting tuberculosis (TB), aiming to overcome limitations of the century-old BCG vaccine and address growing...
- Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, continues to pose a significant global health threat.
- While the United States saw a decline in TB cases from 1993 to 2020, reporting 7,170 cases in 2020, infections began to rise again.
“`html
MIT Scientists Pursue Next-Generation Tuberculosis vaccine
Table of Contents
researchers at the Massachusetts Institute of Technology are developing a novel vaccine candidate targeting tuberculosis (TB), aiming to overcome limitations of the century-old BCG vaccine and address growing global infection rates.
The Challenge of Tuberculosis
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, continues to pose a significant global health threat. According to the World Health Institution (WHO), an estimated 1.3 million people died from TB in 2022, and 10.6 million people fell ill with the disease (WHO, 2023). The current primary vaccine, Bacille Calmette-Guérin (BCG), developed in 1921, offers limited protection in adults and is less effective against pulmonary TB, the most common form of the disease (Stanley et al., 2021).
While the United States saw a decline in TB cases from 1993 to 2020, reporting 7,170 cases in 2020, infections began to rise again. The Centers for Disease Control and Prevention (CDC) reported 7,866 cases in 2021 and a further increase to 10,347 cases in 2023, representing an 8% increase from the previous year (CDC, 2023). This resurgence highlights the need for more effective preventative measures.
MIT’s Peptide-Based Approach
Researchers at MIT, led by Associate Professor Brian Bryson, are pursuing a novel vaccine strategy focused on identifying specific peptides – short chains of amino acids – from Mycobacterium tuberculosis that elicit a strong immune response. The team utilized human macrophage cells,a type of white blood cell crucial for fighting infection,to screen for peptides that activate T cells,the immune cells responsible for eliminating pathogens (MIT News, 2024).
Their research identified 24 peptides that triggered a robust T cell response. The researchers hypothesize that a combination of these peptides could provide broad protection against TB across diverse populations. “Our goal is to develop a vaccine that focuses on antigens that have proven their ability to stimulate the immune response in people who have previously been infected with tuberculosis, to confront the huge burden that the disease represents globally,” Bryson stated (MIT News, 2024).
Why Peptides? The potential Advantages
Customary vaccines frequently enough use weakened or inactivated whole pathogens. Peptide-based vaccines offer several potential advantages:
- Targeted Immune Response: Peptides can be designed to specifically stimulate the desired